Business
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.\n\n\nThe accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte’s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.\n\n\n“Data that will be shared at this year’s ASTRO meeting will demonstrate the Decipher Prostate test’s ability to help clinicians make more informed treatment decisions based on the underlying biology of the individual patient’s prostate cancer and will reinforce that prostate cancer molecular tests are not all created equal nor are they interchangeable,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “Our research collaborators will also present data derived from an analysis of the Decipher Genomics Research for Intelligent Discovery (GRID) database, which help advance understanding of the genomic mechanisms that drive treatment response.”\n\n\nFollowing are details of the six presentations, which will all take place at the San Diego Convention Center:\n\n\n\nDate/Time:\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nMonday, October 2, 2023, 3:10-3:16 p.m. PT\n\n\n\n\n\n\n\n\nTitle:\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nValidation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer\n\n\n\n\n\n\n\n\nAbstract #:\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n158 (oral presentation)\n\n\n\n\n\n\n\n\nPresenter:\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nRyan Phillips, M.D., Ph.D., The Mayo Clinic\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nRoom 6 D/E\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nDate/Time:\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nMonday, October 2, 202...